Skip to main content
SpringerLink
Log in

Adverse events increase cost of CML treatment

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Liou SY, Tran KT, Stephens JM, Onwudiwe NC, Botteman MF.Economic impact of adverse events in chronic myelogenous leukemia: a cost of treatment analysis of dasatinib. Blood 108: 944 (plus poster) abstr. 3309, No. 11, Part 1, Nov 2006

  2. Moyneur E, Barghout V, Denise W, August S, David M, Sheng DM.Medical costs of adverse events associated with patients diagnosed with chronic myeloid leukemia. Blood 108: 948 (plus poster) abstr. 3323, No. 11, Part 1, Nov 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adverse events increase cost of CML treatment. React. Wkly. 1136, 3 (2007). https://doi.org/10.2165/00128415-200711360-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711360-00006

Keywords

Search

Navigation